论文部分内容阅读
目的:观察通络除痹汤联合西药治疗类风湿关节炎(RA)的临床疗效。方法:将100例活动期RA患者随机分为2组各50例,对照组给予口服甲氨蝶呤、来氟米特片治疗,观察组在对照组基础上联合通络除痹汤治疗。治疗3月,观察2组总有效率以及血沉(ESR)、类风湿因子(RF)、C-反应蛋白(CRP)等实验室检测指标的变化情况。结果:总有效率观察组为94.0%,对照组为76.0%,2组比较,差异有显著性意义(P<0.05)。2组治疗后ESR、CRP、RF较前下降(P<0.05,P<0.01)。2组治疗后组间比较,差异均有显著性意义(P<0.05)。2组不良反应发生率比较,差异无显著性意义(P>0.05)。结论:通络除痹汤联合西药治疗RA有效、安全,值得临床推广应用。
Objective: To observe the clinical curative effect of Tongluo Bubi Decoction combined with Western medicine on rheumatoid arthritis (RA). Methods: 100 patients with active RA were randomly divided into two groups of 50 patients. The control group was given methotrexate and leflunomide tablets. The observation group was treated with Tongluo Bibizi on the basis of the control group. After 3 months of treatment, the total effective rate of 2 groups and the changes of laboratory test indexes such as ESR, RF and CRP were observed. Results: The total effective rate was 94.0% in the observation group and 76.0% in the control group. There was significant difference between the two groups (P <0.05). The ESR, CRP and RF in the two groups were significantly lower than before (P <0.05, P <0.01). The difference between the two groups after treatment was significant (P <0.05). There was no significant difference between the two groups in the incidence of adverse reactions (P> 0.05). Conclusion: Tongluobibi decoction combined with western medicine is effective and safe in treating RA. It is worthy of clinical application.